Precigen Inc Form 4 Filings

PRECIGEN, INC. (PGEN) director Nancy H. Agee purchased 3,411 shares of Common Stock in an open-market or private transaction on 2026-08-21 at a price of $7.23 per share. Following this transaction, she directly owns 309,187 shares of PRECIGEN common stock.

PRECIGEN, INC. (PGEN) reported that Chief Legal Officer Donald P. Lehr had 5,208 Restricted Stock Units granted on June 26, 2025 vest on August 23, 2026, converting into an equal number of common shares. To cover income tax withholding, 2,488 shares were withheld at $7.20 per share, leaving a net increase of 2,720 shares. Following these transactions, Lehr directly holds 57,292 shares of Precigen common stock.

PRECIGEN, INC. (PGEN) reported that Chief Financial Officer Harry Thomasian Jr. settled a portion of previously granted Restricted Stock Units (RSUs) on August 23, 2026. He exercised 7,291 RSUs, each convertible into one share of common stock, receiving an equal number of common shares in connection with the vesting of 1/24 of an RSU grant made on June 26, 2025.

To satisfy income tax withholding obligations arising from this RSU settlement, 3,577 shares of Precigen common stock were withheld at a value of $7.20 per share, reported as a code F disposition. Following these transactions, Thomasian directly held 80,209 RSUs. The filing does not report any open-market purchases or sales; reported dispositions relate to tax withholding.

PRECIGEN, INC. (PGEN) reported that Chief Operating Officer Rutul R. Shah exercised stock options and RSUs and sold common shares. On August 21 and 25, 2026, he exercised options for a total of 50,000 shares at $2.33 per share and sold 50,000 shares at $7.50 per share pursuant to a Rule 10b5-1 trading plan. On August 23, 2026, 7,500 RSUs converted into common stock, and 3,647 shares were withheld to satisfy tax obligations, leaving 57,292 RSUs outstanding.

PRECIGEN, INC. (PGEN) reported that Chief Commercial Officer Phil Tennant exercised stock awards and sold shares in August 2026. On August 25, he exercised options to acquire 79,166 shares of common stock at an exercise price of $1.61 per share, reducing that option grant to 120,834 options remaining, and received 79,166 common shares. That same day, he sold 79,166 shares of common stock at $7.50 per share pursuant to a Rule 10b5-1 trading plan.

On August 23, 5,208 Restricted Stock Units vested and converted into the same number of common shares, representing 1/24 of an RSU grant made on June 26, 2025; 57,292 RSUs remained after this vesting. Also on August 23, 2,585 shares were withheld at a price of $7.20 per share to satisfy income tax withholding obligations in connection with the RSU settlement.

PRECIGEN, INC. (PGEN) reported that President and CEO Helen Sabzevari exercised 20,833 Restricted Stock Units into an equal number of shares of common stock on August 23, 2026. The RSUs represent 1/24 of a grant made on June 26, 2025 that vested on that date. Of the resulting shares, 10,184 shares were withheld at $7.20 per share to satisfy income tax withholding obligations. Following the transaction, Sabzevari held 229,167 RSUs directly.

PRECIGEN, INC. Chief Operating Officer Rutul R Shah completed a sale of 32,739 shares of Common Stock on 2026-08-06 at $6.86 per share in a sale classified as an open-market or private transaction under a Rule 10b5-1 trading plan, and now directly holds 465,012 shares.

PRECIGEN, INC. Chief Operating Officer Rutul R. Shah exercised fully vested stock options to acquire 33,772 common shares at $2.33 per share and, on the same date, sold 33,772 shares at $6.50 per share under a Rule 10b5-1 trading plan. After the exercise, he held 123,304 stock options.

PRECIGEN, INC. Chief Financial Officer Harry Thomasian Jr. sold 100,000 shares of common stock on July 31, 2026 at a weighted average price of $6.06 per share, with trades between $6.00 and $6.15, under a Rule 10b5-1 trading plan. After the sale, he directly holds 254,535 shares.

PRECIGEN, INC. Chief Financial Officer Harry Thomasian Jr. reported open-market sales of 200,000 shares of Common Stock under a 10b5-1 trading plan. On June 29, he sold 28,571 shares at a weighted average price of $5.78 per share, followed by 171,429 shares on July 1 at a weighted average price of $5.53 per share. After these transactions, he directly holds 354,535 Common Stock shares.

PRECIGEN, INC. Chief Operating Officer Rutul R. Shah exercised stock options to acquire 42,924 shares of common stock at $2.33 per share, then sold the same 42,924 shares at $5.85 per share in an open-market transaction. The sale was made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person. After these transactions, Shah directly holds 497,751 shares of Precigen common stock and retains options covering 157,076 shares.

PRECIGEN, INC. President and CEO Helen Sabzevari reported an exercise-and-sale transaction in company stock. On June 29, 2026, she exercised stock options to acquire 346,836 shares of common stock at $2.33 per share, then sold the same number of shares in open-market transactions at a weighted average price of $5.89 per share.

The sale was carried out under a pre-established Rule 10b5-1 trading plan and involved multiple trades between $5.75 and $6.04. After these transactions, she directly owns 3,768,872 shares of common stock and holds 500,164 stock options, so the sale represents a relatively small portion of her overall equity position.

PRECIGEN, INC. Chief Financial Officer Harry Thomasian Jr. reported an open-market sale of 41,884 shares of common stock at $4.36 per share. According to the footnote, this sale was a sell-to-cover transaction to satisfy tax withholding obligations upon the vesting of restricted stock units on May 23, 2026. Following the transaction, he directly holds 554,535 shares of Precigen common stock.

PRECIGEN, INC. Chief Commercial Officer Phil Tennant reported a tax-related share sale. On May 28, 2026, he sold 30,272 shares of common stock at $4.36 per share in a sell-to-cover transaction tied to tax withholding on restricted stock units that vested on May 23, 2026. Following this transaction, he directly holds 139,369 common shares, and the filing shows no remaining derivative positions.

PRECIGEN, INC. Chief Operating Officer Rutul R. Shah reported a tax-related stock sale. On May 28, 2026, he sold 42,703 shares of common stock at $4.36 per share in a sell-to-cover transaction to satisfy tax withholding obligations from restricted stock units that vested on May 23, 2026. Following this transaction, he continues to hold 497,751 shares of Precigen common stock directly, indicating he retains a substantial equity stake in the company.

PRECIGEN, INC. reported an insider stock transaction by Chief Legal Officer Donald P. Lehr. On May 28, 2026, he sold 29,131 shares of common stock at $4.36 per share. According to the footnote, this was a sell-to-cover transaction to satisfy tax withholding obligations from restricted stock units that vested on May 23, 2026. After the sale, he continues to hold 755,461 shares of Precigen common stock directly.

PRECIGEN, INC. President and CEO Helen Sabzevari reported a disposition of company stock tied to tax obligations. She sold 119,250 shares of Common Stock at $4.36 per share in a sell-to-cover transaction to satisfy tax withholding upon the vesting of restricted stock units on May 23, 2026. Following this transaction, she directly holds 3,768,872 shares of Precigen common stock.

Precigen, Inc. Chief Financial Officer Harry Thomasian Jr. exercised restricted stock units into common stock as part of his compensation. On May 23, 2026, he acquired 87,500 shares of common stock through the conversion of restricted stock units, with no open-market purchase or sale reported.

Following the transaction, he directly holds 596,419 shares of common stock and 87,500 restricted stock units. The footnotes explain that these RSUs were granted on June 26, 2025, with 50% vesting on May 23, 2026 and the remaining units vesting in equal quarterly installments over the next three years.

PRECIGEN, INC. Chief Commercial Officer Phil Tennant acquired 62,500 shares of common stock on May 23, 2026 through the exercise of restricted stock units. Following the transaction, he directly holds 169,641 common shares. The filing also shows 62,500 RSUs remaining, which will vest in equal quarterly installments over three years.

PRECIGEN, INC. Chief Operating Officer Rutul R. Shah exercised 90,000 restricted stock units into common stock as part of his equity compensation. Following the transaction, he directly holds 540,454 shares of common stock and 90,000 RSUs. The footnotes state that these RSUs were part of a June 26, 2025 grant, with 50% vesting on May 23, 2026 and the remainder scheduled to vest in equal quarterly installments over three years. No open-market purchases or sales were reported; this activity reflects routine vesting and conversion of equity awards.

PRECIGEN, INC. President and CEO Helen Sabzevari exercised restricted stock units that converted into 250,000 shares of common stock on May 23, 2026. Following the transaction, she directly holds 3,888,122 shares of common stock, reflecting an increase in her equity position.

The Form 4 also shows 250,000 restricted stock units outstanding after the transaction. Each RSU represents a contingent right to receive one share of Precigen common stock. The vested portion represents 50% of RSUs granted on June 26, 2025, with the remaining RSUs scheduled to vest in equal quarterly installments over the next three years.

PRECIGEN, INC. Chief Legal Officer Donald P. Lehr exercised restricted stock units into common stock as part of his compensation. He acquired 62,500 shares of common stock on May 23, 2026, increasing his direct holdings to 784,592 shares.

The 62,500 RSUs exercised correspond to 50% of an RSU grant made on June 26, 2025 that vested on May 23, 2026. The remaining portion of that grant, represented by 62,500 RSUs, is scheduled to vest in equal quarterly installments over the next three years.

PRECIGEN, INC. Chief Legal Officer Donald P. Lehr received new equity awards in the form of restricted stock units and stock options. On April 20, 2026, he was granted 107,000 RSUs, each representing one share of common stock, and 358,000 stock options with a $4.11 exercise price.

The RSUs vest 25% on May 23, 2027 and then in equal six‑month installments over three years. The options vest 25% on the same May 23, 2027 date, followed by equal monthly installments for three years, and expire on April 20, 2036. These awards are compensation-related grants rather than open‑market purchases.

PRECIGEN, INC. reported that President and CEO Helen Sabzevari received new equity awards. She was granted 410,000 Restricted Stock Units, each representing one share of common stock, and options on 1,366,000 shares of common stock at an exercise price of $4.11 per share.

The options vest 25% on May 23, 2027 and then in equal monthly installments over three years, while the RSUs vest 25% on the same date and then in equal six‑month installments over three years. No shares were sold in these transactions.

PRECIGEN, INC. Chief Operating Officer Rutul R. Shah received new equity awards as part of his compensation. He was granted 118,000 restricted stock units, each representing the right to receive one share of Precigen common stock. He was also granted options on 395,000 shares of common stock at an exercise price of $4.11 per share.

The options vest 25% on May 23, 2027 and then in equal monthly installments for three years. The RSUs vest 25% on May 23, 2027 and then in equal six-month installments for three years, aligning his incentives with the company’s longer-term performance.

Precigen, Inc. reported that Chief Commercial Officer Phil Tennant received new equity awards. On April 20, 2026, he was granted 115,000 restricted stock units, each representing the right to receive one share of Precigen common stock. He was also granted 385,000 stock options with an exercise price of $4.11 per share, expiring on April 20, 2036.

The options vest 25% on May 23, 2027 and then in equal monthly installments for three years. The RSUs vest 25% on May 23, 2027 and then in equal six-month installments for three years. After these grants, Tennant holds 115,000 RSUs and options covering 385,000 shares, all as direct ownership.

Precigen, Inc.’s Chief Financial Officer Harry Thomasian Jr. reported compensation-related equity grants. He received 120,000 Restricted Stock Units, each representing one share of Precigen common stock, and options on 399,000 shares of common stock at an exercise price of $4.11 per share.

The options vest 25% on May 23, 2027, then in equal monthly installments for three years. The RSUs vest 25% on May 23, 2027, then in equal six‑month installments for three years. The filing shows no open‑market purchases or sales, only awards granted.

PRECIGEN, INC. director and 10% owner Randal J. Kirk reported multiple indirect open-market sales of Common Stock through entities he controls. In total, these entities sold 4,772,781 shares at a weighted average price of $3.30 per share in transactions on March 30, 2026, with individual prices ranging from $3.22 to $3.58.

The sales were made by vehicles including R.J. Kirk Declaration of Trust, various JPK, MGK and ZSK LLCs, the Kellie L. Banks (2009) Long Term Trust and Sunset 2020, LLC. After the transactions, reported indirect holdings included 80,672,818 shares by R.J. Kirk Declaration of Trust and 12,262,741 shares by Sunset 2020, LLC, along with additional positions at entities such as Kapital Joe, Lotus, Third Security and Parkview 2020. Mr. Kirk may be deemed to beneficially own these shares under Rule 13d-3 but disclaims beneficial ownership except to the extent of any pecuniary interest.

PRECIGEN, INC. Chief Financial Officer Harry Thomasian Jr. received a grant of 40,293 restricted stock units on March 18, 2026. Each RSU represents a contingent right to receive one share of Precigen common stock and the RSUs vested immediately upon grant. He then exercised the RSUs into 40,293 shares of common stock at a conversion price of $0.00 per share, bringing his directly held common stock position to 508,919 shares.

PRECIGEN, INC. Chief Commercial Officer Phil Tennant received a grant of 42,110 restricted stock units on March 18, 2026. Each RSU represents one share of common stock and vested immediately on the grant date. The RSUs were then exercised and converted into 42,110 shares of common stock at no cash exercise price, increasing his directly owned common stock holdings to 107,141 shares after these transactions. These actions reflect compensation-related equity awards and derivative exercises, not open-market buying or selling.

PRECIGEN, INC. President and CEO Helen Sabzevari received a grant of 321,100 restricted stock units on March 18, 2026, each representing one share of common stock. The RSUs vested immediately on the grant date as part of her equity compensation.

She then exercised these 321,100 RSUs at $0.00 per unit, converting them into 321,100 shares of common stock. Following the transactions, she directly holds 3,638,122 shares of Precigen common stock. These are compensation-related acquisitions, not open-market purchases.

PRECIGEN, INC. Chief Operating Officer Rutul R. Shah reported equity compensation activity in the form of restricted stock units (RSUs). On March 18, 2026, he received a grant of 44,495 RSUs, each representing one share of common stock, which vested immediately at a price of $0.00 per unit. These RSUs were then exercised and settled into 44,495 shares of Precigen common stock, increasing his direct common stock holdings to 450,454 shares following the transactions.

PRECIGEN, INC. Chief Legal Officer Donald P. Lehr reported a compensation-related equity transaction involving restricted stock units (RSUs). On March 18, 2026, he received a grant of 40,443 RSUs, each representing a contingent right to one share of common stock, at a stated price of $0.0000 per unit.

The footnotes state that these RSUs vested immediately on the grant date. On the same date, Lehr exercised the 40,443 RSUs, converting them into 40,443 shares of common stock at an exercise price of $0.0000. Following this exercise, his directly held common stock position increased to 722,092 shares, and no remaining derivative position is shown in this filing.

This sequence reflects an RSU grant and immediate vesting-and-exercise rather than an open-market purchase or sale, making it a routine equity compensation event for a senior executive.

PRECIGEN, INC. director and major shareholder Randal J. Kirk reported the vesting and exercise of 143,678 restricted stock units into an equal number of shares of common stock at an exercise price of $0.00 per share on March 13, 2026.

The shares are held indirectly through the R.J. Kirk Declaration of Trust, which now holds 81,781,816 shares of Precigen common stock. Additional Form 4 entries list indirect holdings in various trusts, LLCs and related entities that Mr. Kirk controls, with beneficial ownership disclaimed except for any pecuniary interest.

PRECIGEN, INC. director Nancy H. Agee exercised restricted stock units that converted into common shares. On March 13, 2026, 71,839 RSUs vested in full, with each RSU representing one share of Precigen common stock. Following the conversion, she directly holds 305,776 shares of common stock.

This is a compensation-related equity vesting rather than an open-market purchase or sale, and there were no shares reported as sold in connection with this transaction.

PRECIGEN, INC. director Cesar L. Alvarez exercised restricted stock units that had fully vested into common shares. On March 13, 2026, 71,839 RSUs vested in full and were converted into the same number of common shares at no cash exercise price. Following this compensation-related exercise-and-hold transaction, he directly owned 782,909 shares of Precigen common stock.

PRECIGEN, INC. director Frank Steven reported the vesting and exercise of restricted stock units into common shares. On March 13, 2026, 71,839 restricted stock units converted into 71,839 shares of Precigen common stock at a stated price of $0.00 per share, reflecting equity compensation rather than an open-market purchase.

The footnotes state that each RSU represented a contingent right to receive one share of common stock and that the RSUs vested in full on March 13, 2026. After the transaction, Steven directly held 1,226,391 shares of Precigen common stock, with no remaining RSU position shown in this filing.

PRECIGEN, INC. director Vinita D. Gupta reported the vesting and exercise of restricted stock units into common shares. On March 13, 2026, 71,839 RSUs, each representing the right to receive one share of Precigen common stock, vested in full and were converted into 71,839 common shares at no exercise price. Following this transaction, Gupta holds 666,027 shares of Precigen common stock directly, reflecting a routine compensation-related equity acquisition rather than an open-market purchase or sale.

Precigen, Inc. director Fred Hassan exercised restricted stock units into common shares. On March 13, 2026, 71,839 restricted stock units vested in full, with each unit converting into one share of Precigen common stock at an exercise price of $0.00 per share.

Following this derivative exercise, Hassan directly owned 1,243,239 shares of Precigen common stock. The filing shows acquisitions only, with no open-market purchases or sales reported in this transaction.

PRECIGEN, INC. director Jeffrey B. Kindler received common stock through the vesting of previously granted restricted stock units. On March 13, 2026, 71839 RSUs vested in full, converting into 71839 shares of common stock at no exercise price. Following this compensation-related transaction, he directly holds 202100 shares of Precigen common stock, with no reported open-market purchases or sales and no remaining derivative holdings in this filing.

PRECIGEN, INC. director James S. Turley reported the vesting and conversion of restricted stock units into common shares. On March 13, 2026, 71,839 restricted stock units vested in full and were exercised, delivering 71,839 shares of common stock at no cash exercise price.

Following this compensation-related transaction, Turley directly owned 685,417 shares of Precigen common stock. The filing reflects an increase in equity holdings through RSU vesting rather than any open-market purchase or sale.

PRECIGEN, INC. director and greater-than-10% owner Randal J. Kirk reported compensation-related equity awards and updated indirect holdings. On 2026-03-10, an entity he controls, R.J. Kirk Declaration of Trust, received 71,225 restricted stock units, each representing one share of common stock that vests on the one-year anniversary of grant if he continues providing services.

The same trust was also granted 82,147 stock options for common stock at an exercise price of $3.51 per share, expiring on 2036-03-10, and 28,490 shares of common stock at $3.51 per share, bringing its indirect common stock holdings to 81,638,138 shares.

The filing also lists indirect common stock positions held through multiple entities Mr. Kirk controls, including JPK 2008 LLC with 477,492 shares, JPK 2009 LLC with 3,609,057 shares, JPK 2012 LLC with 1,615,634 shares, MGK 2008 LLC with 476,529 shares, MGK 2009 LLC with 3,785,116 shares, MGK 2011 LLC with 1,594,338 shares, ZSK 2008 LLC with 566,162 shares, ZSK 2009 LLC with 341,189 shares, Kellie L. Banks (2009) Long Term Trust with 447,773 shares, Kapital Joe, LLC with 4,598,044 shares, Lotus Capital (2000) Company, Inc. with 1,403 shares, Third Security, LLC with 6,085,471 shares, Parkview 2020 Limited Partnership with 1,096,686 shares, Sunset 2020 LLC with 14,597,161 shares, and shares held by his spouse totaling 1,144,481 shares. The footnotes state Mr. Kirk controls these entities and that shares held by them may be deemed beneficially owned by him, while he disclaims beneficial ownership except to the extent of any pecuniary interest.

PRECIGEN, INC. director James S. Turley reported equity compensation awards rather than open-market trades. On March 10, 2026, he received 35,612 restricted stock units and options for 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. He also received 17,806 shares of common stock issued in lieu of a cash annual retainer of $62,500. The restricted stock units vest in full on March 10, 2027. Following these awards, his direct common stock holdings increased to 613,578 shares.

PRECIGEN, INC. director Jeffrey B. Kindler received new equity awards as part of his board compensation. On March 10, 2026, he was granted 35,612 restricted stock units, each representing one share of common stock, which vest in full on March 10, 2027.

He was also granted options on 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. In addition, he received 19,658 shares of common stock issued in lieu of an annual cash retainer of $69,000, bringing his directly held common stock to 130,261 shares.

PRECIGEN, INC. director Fred Hassan reported receiving new equity awards as compensation. He was granted 35,612 restricted stock units and an option for 41,073 shares of common stock at an exercise price of $3.51 per share, both dated March 10, 2026. He also received 17,948 shares of common stock, with a footnote stating these shares were issued in lieu of an annual cash retainer of $63,000. The restricted stock units vest in full on March 10, 2027, and the stock option expires on March 10, 2036. Following these awards, Hassan directly owns 1,171,400 shares of Precigen common stock.

PRECIGEN, INC. director Vinita D. Gupta reported equity awards received as compensation. On March 10, 2026, she was granted 35,612 restricted stock units representing the right to receive an equal number of common shares, vesting in full on March 10, 2027. She also received options to purchase 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. In addition, she acquired 17,948 shares of common stock, issued in lieu of an annual cash retainer of $63,000, bringing her direct common stock holdings to 594,188 shares after the transactions.

PRECIGEN, INC. director Frank Steven reported equity compensation grants consisting of common shares, restricted stock units, and stock options. He received 14,245 shares of common stock at $3.51 per share, issued in lieu of a $50,000 annual cash retainer, bringing his direct common stock holdings to 1,154,552 shares.

He was also granted 35,612 restricted stock units, each representing one share of common stock and vesting in full on March 10, 2027, plus options to purchase 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. These transactions are compensation-related awards rather than open‑market trading.

PRECIGEN, INC. director Cesar L. Alvarez received equity-based compensation rather than cash. He was issued 17,806 shares of common stock at $3.51 per share in lieu of an annual retainer of $62,500.

Alvarez was also granted 35,612 restricted stock units, each representing one share of common stock, which vest in full on March 10, 2027. In addition, he received an option to purchase 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. Following these awards, he directly owns 711,070 common shares. These are compensation grants, not open-market purchases.

PRECIGEN, INC. director Nancy H. Agee received equity-based compensation on March 10, 2026. She was granted 35,612 restricted stock units, each representing one share of common stock, which vest in full on March 10, 2027. She also received an option to purchase 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. In addition, she was issued 16,096 shares of common stock in lieu of an annual cash retainer of $56,500. Following these awards, her directly held common stock position reported in this filing is 233,937 shares.